Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 0.46 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | NPY4R | P50391 | 7/20 | 0.41 |
| ▸ | NPY1R | P25929 | 5/20 | 0.41 |
| ▸ | NPY2R | P49146 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14627405 | 0.99 | GNAI3 (0.51) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| Hydrochloric Acid SCHEMBL2460422 | 0.91 | GNAI3 (0.48) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL446551 | 0.89 | GNAI3 (0.49) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL16209914 | 0.88 | GNAI3 (0.57) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| Hydrochloric Acid SCHEMBL5540410 | 0.86 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL1521785 | 0.82 | DPP7 (0.48) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL25670816 | 0.82 | GNAI3 (0.50) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL24420660 | 0.82 | DPP7 (0.73) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL27115127 | 0.82 | DPP7 (0.73) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL18868846 | 0.81 | DPP7 (0.51) | GNAI3GNAO1GNAI1DPP7RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771206-B1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9387262-B2 | Coated lipid complexes and their use | SILENCE THERAPEUTICS GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| EP-2992902-A1 | LIPID COMPLEXES COATED WITH PEG AND THEIR USES | Silence Therapeutics GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9125820-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| EP-1830888-B1 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20150031752-A1 | COATED LIPID COMPLEXES AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| US-8735453-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20130165381-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2013-06-27 | — | — | US | disclosed |
| CN-101287497-B | Lipid complexes coated with peg and their use | SILENCE THERAPEUTICS AG | 2013-03-06 | — | — | CN | disclosed |
| US-8357722-B2 | Lipids, lipid complexes and use thereof | Silence Therpeutics AG (DE) | 2013-01-22 | — | — | US | disclosed |
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20110294871-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-8017804-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS AG (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | SILENCE THERAPEUTICS AG (DE) | 2008-11-06 | — | — | US | disclosed |
| CN-101287497-A | Lipid complexes coated with peg and their use | SILENCE THERAPEUTICS AG (DE) | 2008-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | RRM1 2729/4885DPP4 345/4885GNAI3 2142/4885 |
| US-20110294871-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | RRM1 2729/4885DPP4 345/4885GNAI3 2142/4885 |
| US-20130165381-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | RRM1 2846/4885DPP4 223/4885GNAI3 2535/4885 |
| US-20100062967-A1 | COATED LIPID COMPLEXES AND THEIR USE | HDLBP, NR1H3, CETP | RRM1 4043/4885DPP4 2985/4885GNAI3 2209/4885 |
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | RRM1 2846/4885DPP4 223/4885GNAI3 2535/4885 |
| US-20150031752-A1 | COATED LIPID COMPLEXES AND THEIR USE | HDLBP, NR1H3, CETP | RRM1 4043/4885DPP4 2985/4885GNAI3 2209/4885 |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | MGLL, LIPA, SGMS1 | RRM1 2638/4885DPP4 346/4885GNAI3 1929/4885 |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | RRM1 2846/4885DPP4 223/4885GNAI3 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.